Joyce Allene Goldstein

Usmani, K. A., Rose, R. L., Goldstein, J. A., Taylor, W. G., Brimfield, A. A., & Hodgson, E. (2002). In vitro human metabolism and interactions of repellent N,N-diethyl-M-toluamide. DRUG METABOLISM AND DISPOSITION, 30(3), 289–294. https://doi.org/10.1124/dmd.30.3.289

Dai, D., Tang, J., Rose, R., Hodgson, E., Bienstock, R. J., Mohrenweiser, H. W., & Goldstein, J. A. (2001). Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. Journal of Pharmacology and Experimental Therapeutics, 299(3), 825–831.

Lankford, S. M., Bai, S. A., & Goldstein, J. A. (2000). Cloning of canine cytochrome P450 2E1 CDNA: identification and characterization of two variant alleles. Drug Metabolism and Disposition, 28(8), 981–986.

Klose, T. S., Blaisdell, J. A., & Goldstein, J. A. (1999). Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 13(6), 289–295. https://doi.org/10.1002/(SICI)1099-0461(1999)13:6<289::AID-JBT1>3.0.CO;2-N

Shetty, P. N., & Hough-Goldstein, J. A. (1998). Behavioral response of Podisus maculiventris (Hemiptera : Pentatomidae) to its synthetic pheromone. JOURNAL OF ENTOMOLOGICAL SCIENCE, 33(1), 72–81. https://doi.org/10.18474/0749-8004-33.1.72

Luo, G., Zeldin, D. C., Blaisdell, J. A., Hodgson, E., & Goldstein, J. A. (1998). Cloning and expression of murine CYP2Cs and their ability to metabolize arachidonic acid. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 357(1), 45–57. https://doi.org/10.1006/abbi.1998.0806

Klose, T. S., Ibeanu, G. C., Ghanayem, B. I., Pedersen, L. G., Li, L. P., Hall, S. D., & Goldstein, J. A. (1998). Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 357(2), 240–248. https://doi.org/10.1006/abbi.1998.0826

Blaisdell, J., Goldstein, J. A., & Bai, S. A. (1998). Isolation of a new canine cytochrome P450 cDNA from the cytochrome P450 2C subfamily (CYP2C41) and evidence for polymorphic differences in its expression. Drug Metabolism and Disposition, 26(3), 278–283.

SullivanKlose, T. H., Ghanayem, B. I., Bell, D. A., Zhang, Z. Y., Kaminsky, L. S., Shenfield, G. M., … Goldstein, J. A. (1996). The role of the CYP2C9-Leu(359) allelic variant in the tolbutamide polymorphism. PHARMACOGENETICS, 6(4), 341–349. https://doi.org/10.1097/00008571-199608000-00007